Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
389 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cystic Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H2 2016', provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects - The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Cystic Fibrosis Overview 8 Therapeutics Development 9 Cystic Fibrosis - Therapeutics under Development by Companies 11 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 17 Cystic Fibrosis - Pipeline Products Glance 18 Cystic Fibrosis - Products under Development by Companies 22 Cystic Fibrosis - Products under Investigation by Universities/Institutes 30 Cystic Fibrosis - Companies Involved in Therapeutics Development 31 Cystic Fibrosis - Therapeutics Assessment 105 Drug Profiles 119 Cystic Fibrosis - Dormant Projects 349 Cystic Fibrosis - Discontinued Products 360 Cystic Fibrosis - Product Development Milestones 361 Appendix 373
List of Tables
Number of Products under Development for Cystic Fibrosis, H2 2016 24 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016 25 Number of Products under Development by Companies, H2 2016 26 Number of Products under Development by Companies, H2 2016 (Contd..1) 27 Number of Products under Development by Companies, H2 2016 (Contd..2) 28 Number of Products under Development by Companies, H2 2016 (Contd..3) 29 Number of Products under Development by Companies, H2 2016 (Contd..4) 30 Number of Products under Development by Companies, H2 2016 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2016 32 Comparative Analysis by Late Stage Development, H2 2016 33 Comparative Analysis by Clinical Stage Development, H2 2016 34 Comparative Analysis by Early Stage Development, H2 2016 35 Comparative Analysis by Unknown Stage Development, H2 2016 36 Products under Development by Companies, H2 2016 37 Products under Development by Companies, H2 2016 (Contd..1) 38 Products under Development by Companies, H2 2016 (Contd..2) 39 Products under Development by Companies, H2 2016 (Contd..3) 40 Products under Development by Companies, H2 2016 (Contd..4) 41 Products under Development by Companies, H2 2016 (Contd..5) 42 Products under Development by Companies, H2 2016 (Contd..6) 43 Products under Development by Companies, H2 2016 (Contd..7) 44 Products under Investigation by Universities/Institutes, H2 2016 45 Cystic Fibrosis - Pipeline by Actelion Ltd, H2 2016 46 Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2016 47 Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2016 48 Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016 49 Cystic Fibrosis - Pipeline by Arch Biopartners, Inc., H2 2016 50 Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016 51 Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 52 Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2016 53 Cystic Fibrosis - Pipeline by Bayer AG, H2 2016 54 Cystic Fibrosis - Pipeline by BioAegis Therapeutics, Inc., H2 2016 55 Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 56 Cystic Fibrosis - Pipeline by Calista Therapeutics, Inc., H2 2016 57 Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 58 Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2016 59 Cystic Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016 60 Cystic Fibrosis - Pipeline by Cilian AG, H2 2016 61 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2016 62 Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2016 63 Cystic Fibrosis - Pipeline by CSA Biotechnologies LLC , H2 2016 64 Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 65 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2016 66 Cystic Fibrosis - Pipeline by Editas Medicine, Inc., H2 2016 67 Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals, Ltd., H2 2016 68 Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H2 2016 69 Cystic Fibrosis - Pipeline by Eumedica SA, H2 2016 70 Cystic Fibrosis - Pipeline by Galapagos NV, H2 2016 71 Cystic Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016 72 Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016 73 Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016 74 Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2016 75 Cystic Fibrosis - Pipeline by ID Pharma Co., Ltd., H2 2016 76 Cystic Fibrosis - Pipeline by Immun System I.M.S. AB, H2 2016 77 Cystic Fibrosis - Pipeline by Insmed Incorporated, H2 2016 78 Cystic Fibrosis - Pipeline by Invion Limited, H2 2016 79 Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H2 2016 80 Cystic Fibrosis - Pipeline by Kamada Ltd., H2 2016 81 Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 82 Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016 83 Cystic Fibrosis - Pipeline by Lakewood-Amedex Inc, H2 2016 84 Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2016 85 Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H2 2016 86 Cystic Fibrosis - Pipeline by Mast Therapeutics, Inc., H2 2016 87 Cystic Fibrosis - Pipeline by Merck & Co., Inc., H2 2016 88 Cystic Fibrosis - Pipeline by Microbion Corporation, H2 2016 89 Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H2 2016 90 Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H2 2016 91 Cystic Fibrosis - Pipeline by Novabiotics Limited, H2 2016 92 Cystic Fibrosis - Pipeline by Novartis AG, H2 2016 93 Cystic Fibrosis - Pipeline by OSE Immunotherapeutics, H2 2016 94 Cystic Fibrosis - Pipeline by Paranta Biosciences Limited, H2 2016 95 Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H2 2016 96 Cystic Fibrosis - Pipeline by Pfizer Inc., H2 2016 97 Cystic Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 98 Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 99 Cystic Fibrosis - Pipeline by Polyphor Ltd., H2 2016 100 Cystic Fibrosis - Pipeline by Progenra, Inc., H2 2016 101 Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 102 Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H2 2016 103 Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 104 Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H2 2016 105 Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H2 2016 106 Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016 107 Cystic Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016 108 Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H2 2016 109 Cystic Fibrosis - Pipeline by Savara Inc., H2 2016 110 Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H2 2016 111 Cystic Fibrosis - Pipeline by Shire Plc, H2 2016 112 Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2016 113 Cystic Fibrosis - Pipeline by TGV-Laboratories, H2 2016 114 Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 115 Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2016 116 Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 117 Cystic Fibrosis - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 118 Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H2 2016 119 Assessment by Monotherapy Products, H2 2016 120 Assessment by Combination Products, H2 2016 121 Number of Products by Stage and Target, H2 2016 123 Number of Products by Stage and Mechanism of Action, H2 2016 127 Number of Products by Stage and Route of Administration, H2 2016 131 Number of Products by Stage and Molecule Type, H2 2016 133 Cystic Fibrosis - Dormant Projects, H2 2016 364 Cystic Fibrosis - Dormant Projects (Contd..1), H2 2016 365 Cystic Fibrosis - Dormant Projects (Contd..2), H2 2016 366 Cystic Fibrosis - Dormant Projects (Contd..3), H2 2016 367 Cystic Fibrosis - Dormant Projects (Contd..4), H2 2016 368 Cystic Fibrosis - Dormant Projects (Contd..5), H2 2016 369 Cystic Fibrosis - Dormant Projects (Contd..6), H2 2016 370 Cystic Fibrosis - Dormant Projects (Contd..7), H2 2016 371 Cystic Fibrosis - Dormant Projects (Contd..8), H2 2016 372 Cystic Fibrosis - Dormant Projects (Contd..9), H2 2016 373 Cystic Fibrosis - Dormant Projects (Contd..10), H2 2016 374 Cystic Fibrosis - Discontinued Products, H2 2016 375
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
